Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 128

1.

Clinicopathological features of patients with malignant mesothelioma in a multicenter, case-control study: no role for ABO-Rh blood groups.

Utkan G, Ürün Y, Cangir AK, Kılıç D, Özdemir NY, Oztuna DG, Bulut E, Arslan ÜY, Koçer M, Kavukçu Ş, İçli F.

Asian Pac J Cancer Prev. 2013;14(1):249-53.

2.

Comparison of cisplatin plus pemetrexed and cisplatin plus gemcitabine for the treatment of malignant pleural mesothelioma in Japanese patients.

Shukuya T, Takahashi T, Imai H, Tokito T, Ono A, Akamatsu H, Taira T, Kenmotsu H, Naito T, Murakami H, Endo M, Yamamoto N.

Respir Investig. 2014 Mar;52(2):101-6. doi: 10.1016/j.resinv.2013.07.002. Epub 2013 Sep 13.

PMID:
24636265
3.

Second-line gemcitabine-based chemotherapy regimens improve overall 3-year survival rate in patients with malignant pleural mesothelioma: a multicenter retrospective study.

Mutlu H, Gündüz S, Karaca H, Büyükçelik A, Cihan YB, Erden A, Akca Z, Coşkun HS.

Med Oncol. 2014 Aug;31(8):74. doi: 10.1007/s12032-014-0074-9. Epub 2014 Jun 24.

PMID:
24958517
4.

Gemcitabine and vinorelbine in pemetrexed-pretreated patients with malignant pleural mesothelioma.

Zucali PA, Ceresoli GL, Garassino I, De Vincenzo F, Cavina R, Campagnoli E, Cappuzzo F, Salamina S, Soto Parra HJ, Santoro A.

Cancer. 2008 Apr 1;112(7):1555-61. doi: 10.1002/cncr.23337.

5.

Lack of any relationship between ABO and Rh blood groups and clinicopathological features in patients with gastrointestinal stromal tumors: Turkish Oncology Group.

Ürün Y, Utkan G, Yalcin Ş, Coşkun HŞ, Koçer M, Özdemir NY, Kaplan MA, Arslan ÜY, Özdemir F, Öztuna D, Akbulut H, İçli F.

Asian Pac J Cancer Prev. 2012;13(8):4129-31.

6.

[Prognosis related clinical and molecular factors in malignant pleural mesothelioma].

Wang YY, Zhang H, Bai H, Wang SH, Wu MN, An TT, Zhao J, Zhuo ML, Duan JC, Wang ZJ, Wang J.

Zhonghua Jie He He Hu Xi Za Zhi. 2013 Mar;36(3):162-8. Chinese.

PMID:
23856136
7.

Second-line chemotherapy in malignant pleural mesothelioma: results of a retrospective multicenter survey.

Zucali PA, Simonelli M, Michetti G, Tiseo M, Ceresoli GL, Collovà E, Follador A, Lo Dico M, Moretti A, De Vincenzo F, Lorenzi E, Perrino M, Giordano L, Farina G, Santoro A, Garassino M.

Lung Cancer. 2012 Mar;75(3):360-7. doi: 10.1016/j.lungcan.2011.08.011. Epub 2011 Sep 19.

PMID:
21937142
8.

Association of ABO blood group and risk of lung cancer in a multicenter study in Turkey.

Urun Y, Utkan G, Cangir AK, Oksuzoglu OB, Ozdemir N, Oztuna DG, Kocaman G, Coşkun HŞ, Kaplan MA, Yuksel C, Demirkazik A, Icli F.

Asian Pac J Cancer Prev. 2013;14(5):2801-3.

9.

Pemetrexed plus gemcitabine as first-line chemotherapy for patients with peritoneal mesothelioma: final report of a phase II trial.

Simon GR, Verschraegen CF, Jänne PA, Langer CJ, Dowlati A, Gadgeel SM, Kelly K, Kalemkerian GP, Traynor AM, Peng G, Gill J, Obasaju CK, Kindler HL.

J Clin Oncol. 2008 Jul 20;26(21):3567-72. doi: 10.1200/JCO.2007.15.2868.

PMID:
18640937
10.

ABO and Rh blood groups and risk of colorectal adenocarcinoma.

Urun Y, Ozdemir NY, Utkan G, Akbulut H, Savas B, Oksuzoglu B, Oztuna DG, Dogan I, Yalcin B, Senler FC, Onur H, Demirkazik A, Zengin N, Icli F.

Asian Pac J Cancer Prev. 2012;13(12):6097-100.

11.

Second-line (post-study) chemotherapy received by patients treated in the phase III trial of pemetrexed plus cisplatin versus cisplatin alone in malignant pleural mesothelioma.

Manegold C, Symanowski J, Gatzemeier U, Reck M, von Pawel J, Kortsik C, Nackaerts K, Lianes P, Vogelzang NJ.

Ann Oncol. 2005 Jun;16(6):923-7. Epub 2005 Apr 11.

PMID:
15824080
12.

Phase I trial of cisplatin, pemetrexed, and imatinib mesylate in chemonaive patients with unresectable malignant pleural mesothelioma.

Tsao AS, Harun N, Lee JJ, Heymach J, Pisters K, Hong WK, Fujimoto J, Wistuba I.

Clin Lung Cancer. 2014 May;15(3):197-201. doi: 10.1016/j.cllc.2013.12.008. Epub 2013 Dec 27.

13.

The efficacy of the frontline platinum-based combination chemotherapy in malignant peritoneal mesothelioma.

Kim ST, Park JY, Lee J, Park JO, Park YS, Lim HY, Kang WK, Park SH.

Jpn J Clin Oncol. 2010 Nov;40(11):1031-6. doi: 10.1093/jjco/hyq083. Epub 2010 Jun 9.

PMID:
20534685
14.

Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma.

Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffie P, Gatzemeier U, Boyer M, Emri S, Manegold C, Niyikiza C, Paoletti P.

J Clin Oncol. 2003 Jul 15;21(14):2636-44.

PMID:
12860938
15.

Phase II clinical trial of amatuximab, a chimeric antimesothelin antibody with pemetrexed and cisplatin in advanced unresectable pleural mesothelioma.

Hassan R, Kindler HL, Jahan T, Bazhenova L, Reck M, Thomas A, Pastan I, Parno J, O'Shannessy DJ, Fatato P, Maltzman JD, Wallin BA.

Clin Cancer Res. 2014 Dec 1;20(23):5927-36. doi: 10.1158/1078-0432.CCR-14-0804. Epub 2014 Sep 17.

16.

The efficacy of pemetrexed and bevacizumab intrapleural injection for malignant pleural mesothelioma-mediated malignant pleural effusion.

Chen D, Li X, Zhao H, Fu Y, Yao F, Hu J, Du N.

Indian J Cancer. 2014 Mar;51 Suppl 3:e82-5. doi: 10.4103/0019-509X.154058.

17.

A multicenter phase II study of cisplatin, pemetrexed, and bevacizumab in patients with advanced malignant mesothelioma.

Dowell JE, Dunphy FR, Taub RN, Gerber DE, Ngov L, Yan J, Xie Y, Kindler HL.

Lung Cancer. 2012 Sep;77(3):567-71. doi: 10.1016/j.lungcan.2012.05.111. Epub 2012 Jul 4.

PMID:
22770372
18.

Cisplatin and gemcitabine in malignant mesothelioma.

Nowak AK, Byrne MJ.

Ann Oncol. 2005 Oct;16(10):1711. Epub 2005 Jul 6. No abstract available.

PMID:
16000339
19.

Single-arm, open label study of pemetrexed plus cisplatin in chemotherapy naïve patients with malignant pleural mesothelioma: outcomes of an expanded access program.

Obasaju CK, Ye Z, Wozniak AJ, Belani CP, Keohan ML, Ross HJ, Polikoff JA, Mintzer DM, Monberg MJ, Jänne PA; Pemetrexed Expanded Access Program Investigators.

Lung Cancer. 2007 Feb;55(2):187-94. Epub 2006 Nov 7.

PMID:
17092602
20.

Folylpoly-glutamate synthetase expression is associated with tumor response and outcome from pemetrexed-based chemotherapy in malignant pleural mesothelioma.

Christoph DC, Asuncion BR, Mascaux C, Tran C, Lu X, Wynes MW, Gauler TC, Wohlschlaeger J, Theegarten D, Neumann V, Hepp R, Welter S, Stamatis G, Tannapfel A, Schuler M, Eberhardt WE, Hirsch FR.

J Thorac Oncol. 2012 Sep;7(9):1440-8.

Supplemental Content

Support Center